Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemarituzumab plus chemotherapy and nivolumab vs chemotherapy and nivolumab in FGFR2b-positive advanced gastric/GEJ cancer
jRCT2031210669Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of bemarituzumab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Amgen. Primary endpoints: Part 1: Number of Participants Who Experienced DLTs, Part 1: Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAEs) and 6 more. Started Mar 2022; status: completed.
02
Drugs
bemarituzumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031210669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210669.